Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Marco Spalletti"'
Autor:
Marco Spalletti, Valentina Lasala, Paolo Cameli, Laura Bergantini, Marco Saletti, Valerio Beltrami, Elena Bargagli, Miriana d’Alessandro
Publikováno v:
Allergies, Vol 3, Iss 3, Pp 177-183 (2023)
Pollen food allergy syndrome (PFAS) is an allergic reaction to specific foods in persons previously sensitised to pollen. The diagnosis of PFAS is made after taking a patient’s medical history and, in some cases, conducting skin tests and oral food
Externí odkaz:
https://doaj.org/article/5d32e18b57e3481aa6688c4c52755e74
Autor:
Sara Gangi, Laura Bergantini, Paolo Cameli, Irene Paggi, Marco Spalletti, Fabrizio Mezzasalma, Elena Bargagli, Miriana d’Alessandro
Publikováno v:
Biomedicines, Vol 12, Iss 3, p 630 (2024)
Introduction: Pulmonary fibrosis is an irreversible condition that may be caused by known (including viral triggers such as SARS-CoV-2) and unknown insults. The latter group includes idiopathic pulmonary fibrosis (IPF), which is a chronic, progressiv
Externí odkaz:
https://doaj.org/article/9c6a3633c2d44b189343dd0935c86965
Autor:
Lucia Vietri, Paolo Cameli, Marco Perruzza, Behar Cekorja, Laura Bergantini, Miriana d’Alessandro, Rosa Metella Refini, Maria Pieroni, Antonella Fossi, David Bennett, Marco Spalletti, Maria Antonietta Mazzei, Piersante Sestini, Paola Rottoli, Elena Bargagli
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 14 (2020)
Background: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and has a median survival after diagnosis of 2–5 years. Pirfenidone is the first approved antifibrotic drug for the treatment of IPF. Here we repor
Externí odkaz:
https://doaj.org/article/d3caa0d35a414d2eab02e76af6f8e9b5
Autor:
Miriana d'Alessandro, Marco Perruzza, Piersante Sestini, Maria Pieroni, Maria Antonietta Mazzei, Elena Bargagli, David Bennett, Lucia Vietri, Paolo Cameli, Marco Spalletti, Antonella Fossi, Laura Bergantini, Behar Cekorja, Paola Rottoli, Rosa Metella Refini
Publikováno v:
Therapeutic Advances in Respiratory Disease
Therapeutic Advances in Respiratory Disease, Vol 14 (2020)
Therapeutic Advances in Respiratory Disease, Vol 14 (2020)
Background: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and has a median survival after diagnosis of 2–5 years. Pirfenidone is the first approved antifibrotic drug for the treatment of IPF. Here we repor